Summary
This report provides an overview of the pipeline landscape for depression and anxiety disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD) and depression, and features dormant and discontinued products.
PTSD is a mental health condition that is triggered by either experiencing or witnessing a traumatic event. Symptoms include flashbacks, nightmares and severe anxiety, as well as uncontrollable thoughts about the event. Treatment includes antidepressants and cognitive therapy. There are 38 products in development for this indication.
OCD is characterized by unreasonable thoughts and fears (obsessions) that lead to repetitive behaviors (compulsions). Symptoms include having repeated thoughts or images about many different things, such as fear of germs, dirt, or intruders, acts of violence, hurting loved ones, doing the same rituals over and over such as washing hands, locking and unlocking doors, counting, keeping unneeded items, or repeating the same steps again and again. Treatment includes antidepressants and psychiatric medications. There are nine products in development for this indication.
Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches. Treatment includes antidepressants, mood stabilizers and antipsychotics. There are 212 products in development for this indication.
Molecular targets acted on by products in development for depression and anxiety disorders include neurotransmitter receptors such as glutamate receptors and 5-hydroxytryptamine receptors. Companies operating in this pipeline space include NeuroRx, Amorsa Therapeutics and Johnson & Johnson.
Scope
- Which companies are the most active within each pipeline?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?
Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
'
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 8
2 Introduction 9
2.1 Depression and Anxiety Disorders Report Coverage 9
2.2 Post-Traumatic Stress Disorder (PTSD) - Overview 9
2.3 Obsessive-Compulsive Disorder - Overview 9
2.4 Depression - Overview 9
3 Therapeutics Development 10
3.1 Post-Traumatic Stress Disorder (PTSD) 10
3.2 Obsessive-Compulsive Disorder 17
3.3 Depression 20
4 Therapeutics Assessment 41
4.1 Post-Traumatic Stress Disorder (PTSD) 41
4.2 Obsessive-Compulsive Disorder 49
4.3 Depression 54
5 Companies Involved in Therapeutics Development 68
5.1 Post-Traumatic Stress Disorder (PTSD) 68
5.2 Obsessive-Compulsive Disorder 78
5.3 Depression 80
6 Dormant Projects 122
6.1 Post-Traumatic Stress Disorder (PTSD) 122
6.2 Obsessive-Compulsive Disorder 124
6.3 Depression 125
7 Discontinued Products 141
7.1 Post-Traumatic Stress Disorder (PTSD) 141
7.2 Obsessive-Compulsive Disorder 141
7.3 Depression 142
8 Product Development Milestones 147
8.1 Post-Traumatic Stress Disorder (PTSD) 147
8.2 Obsessive-Compulsive Disorder 156
8.3 Depression 157
9 Appendix 174
9.1 Methodology 174
9.2 Coverage 174
9.3 Secondary Research 174
9.4 Primary Research 174
9.5 Expert Panel Validation 174
9.6 Contact Us 175
9.7 Disclaimer 175
1.1 List of Tables
Table 1: Number of Products under Development for Post-Traumatic Stress Disorder (PTSD) 10
Table 2: Number of Products under Development by Companies, Post-Traumatic Stress Disorder (PTSD) 12
Table 3: Number of Products under Development by Universities/Institutes, Post-Traumatic Stress Disorder (PTSD) 13
Table 4: Products under Development by Companies, Post-Traumatic Stress Disorder (PTSD) 14
Table 5: Products under Development by Universities/Institutes, Post-Traumatic Stress Disorder (PTSD) 16
Table 6: Number of Products under Development for Obsessive-Compulsive Disorder 17
Table 7: Number of Products under Development by Companies, Obsessive-Compulsive Disorder 18
Table 8: Number of Products under Development by Universities/Institutes, Obsessive-Compulsive Disorder 19
Table 9: Products under Development by Companies, Obsessive-Compulsive Disorder 19
Table 10: Products under Development by Universities/Institutes, Obsessive-Compulsive Disorder 19
Table 11: Number of Products under Development for Depression 20
Table 12: Number of Products under Development by Companies, Depression 22
Table 13: Number of Products under Development by Universities/Institutes, Depression 27
Table 14: Products under Development by Companies, Depression 28
Table 15: Products under Development by Universities/Institutes, Depression 39
Table 16: Number of Products by Stage and Target, Post-Traumatic Stress Disorder (PTSD) 42
Table 17: Number of Products by Stage and Mechanism of Action, Post-Traumatic Stress Disorder (PTSD) 45
Table 18: Number of Products by Stage and Route of Administration, Post-Traumatic Stress Disorder (PTSD) 47
Table 19: Number of Products by Stage and Molecule Type, Post-Traumatic Stress Disorder (PTSD) 49
Table 20: Number of Products by Stage and Target, Obsessive-Compulsive Disorder 50
Table 21: Number of Products by Stage and Mechanism of Action, Obsessive-Compulsive Disorder 52
Table 22: Number of Products by Stage and Route of Administration, Obsessive-Compulsive Disorder 53
Table 23: Number of Products by Stage and Molecule Type, Obsessive-Compulsive Disorder 53
Table 24: Number of Products by Stage and Target, Depression 55
Table 25: Number of Products by Stage and Mechanism of Action, Depression 60
Table 26: Number of Products by Stage and Route of Administration, Depression 65
Table 27: Number of Products by Stage and Molecule Type, Depression 67
Table 28: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Actinogen Medical Ltd 68
Table 29: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Addex Therapeutics Ltd 69
Table 30: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Amorsa Therapeutics Inc 69
Table 31: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Aptinyx Inc 69
Table 32: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Azevan Pharmaceuticals Inc 70
Table 33: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Bionomics Ltd 70
Table 34: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Catalyst Pharmaceuticals Inc 71
Table 35: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Chronos Therapeutics Ltd 71
Table 36: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Corcept Therapeutics Inc 72
Table 37: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Eli Lilly and Co 72
Table 38: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Embera NeuroTherapeutics Inc 73
Table 39: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Immodulon Therapeutics Ltd 73
Table 40: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Johnson & Johnson 74
Table 41: Post-Traumatic Stress Disorder (PTSD) - Pipeline by NeuroNascent Inc 74
Table 42: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Omeros Corp 75
Table 43: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Otsuka Holdings Co Ltd 76
Table 44: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Pragma Therapeutics SAS 76
Table 45: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Sanofi 76
Table 46: Post-Traumatic Stress Disorder (PTSD) - Pipeline by SpringWorks Therapeutics LLC 77
Table 47: Post-Traumatic Stress Disorder (PTSD) - Pipeline by Tonix Pharmaceuticals Holding Corp 77
Table 48: Obsessive-Compulsive Disorder - Pipeline by Addex Therapeutics Ltd 78
Table 49: Obsessive-Compulsive Disorder - Pipeline by Amorsa Therapeutics Inc 78
Table 50: Obsessive-Compulsive Disorder - Pipeline by Biohaven Pharmaceutical Holding Company Ltd 79
Table 51: Obsessive-Compulsive Disorder - Pipeline by Omeros Corp 79
1.2 List of Figures
Figure 1: Number of Products under Development for Post-Traumatic Stress Disorder (PTSD) 10
Figure 2: Number of Products under Development by Companies, Post-Traumatic Stress Disorder (PTSD) 11
Figure 3: Number of Products under Development by Universities/Institutes, Post-Traumatic Stress Disorder (PTSD) 13
Figure 4: Number of Products under Development for Obsessive-Compulsive Disorder 17
Figure 5: Number of Products under Development by Companies, Obsessive-Compulsive Disorder 18
Figure 6: Number of Products under Development for Depression 20
Figure 7: Number of Products under Development by Companies, Depression 21
Figure 8: Number of Products under Development by Universities/Institutes, Depression 26
Figure 9: Number of Products by Top 10 Targets, Post-Traumatic Stress Disorder (PTSD) 41
Figure 10: Number of Products by Stage and Top 10 Targets, Post-Traumatic Stress Disorder (PTSD) 41
Figure 11: Number of Products by Top 10 Mechanism of Actions, Post-Traumatic Stress Disorder (PTSD) 43
Figure 12: Number of Products by Stage and Top 10 Mechanism of Actions, Post-Traumatic Stress Disorder (PTSD) 44
Figure 13: Number of Products by Routes of Administration, Post-Traumatic Stress Disorder (PTSD) 46
Figure 14: Number of Products by Stage and Routes of Administration, Post-Traumatic Stress Disorder (PTSD) 47
Figure 15: Number of Products by Molecule Types, Post-Traumatic Stress Disorder (PTSD) 48
Figure 16: Number of Products by Stage and Molecule Types, Post-Traumatic Stress Disorder (PTSD) 48
Figure 17: Number of Products by Top 10 Targets, Obsessive-Compulsive Disorder 49
Figure 18: Number of Products by Stage and Top 10 Targets, Obsessive-Compulsive Disorder 50
Figure 19: Number of Products by Top 10 Mechanism of Actions, Obsessive-Compulsive Disorder 51
Figure 20: Number of Products by Stage and Top 10 Mechanism of Actions, Obsessive-Compulsive Disorder 51
Figure 21: Number of Products by Stage and Routes of Administration, Obsessive-Compulsive Disorder 52
Figure 22: Number of Products by Stage and Top 10 Molecule Types, Obsessive-Compulsive Disorder 53
Figure 23: Number of Products by Top 10 Targets, Depression 54
Figure 24: Number of Products by Stage and Top 10 Targets, Depression 54
Figure 25: Number of Products by Top 10 Mechanism of Actions, Depression 59
Figure 26: Number of Products by Stage and Top 10 Mechanism of Actions, Depression 59
Figure 27: Number of Products by Routes of Administration, Depression 64
Figure 28: Number of Products by Stage and Routes of Administration, Depression 65
Figure 29: Number of Products by Molecule Types, Depression 66
Figure 30: Number of Products by Stage and Molecule Types, Depression 66
